Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 22, 2018
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 22, 2018

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/22/18 - DynaMAXX Intl Launches Bold New Company
DyanMAXX Intl, a nutritional supplement announces launch of sister company, Gemini Network, LLC, to focus on booming Hemp Oil market.
4/22/18 - Expert urges NAFDAC to enforce use of plastic pallets in food, pharmaceutical industry
A packaging expert, Ravi Kanwal, has called on National Agency for Food, Drug Administration and Control to enforce the use of plastic pallets in packaging food and pharmaceutical products. Kanwal said that the company was introducing into Nigeria injection molded plastic pallets which was produced through robotic technology. We have been produc
4/22/18 - Global Probiotic Dietary Supplement Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type & Application, Forecast to 2023
Market Study Report Add New Global Probiotic Dietary Supplement Market by Manufacturers, Countries, Type and Application, forecast to 2023 to its research database presenting an informative study covering the market with detailed analysis. The report...
4/22/18 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 11759) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Arthritis Advisory Committee to discuss new drug application 207924, for baricitinib tablets, submitted by Eli Lilly and Company, for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate resp
4/22/18 - Livingston mom battles breast cancer with experimental treatments to help other patients [Detroit Free Press]
Kimberlie Newton can't wallow in the agony of regret. She has enrolled in a clinical trial at the Barbara Ann Karmanos Cancer Institute, hoping that by trying experimental drugs and therapies that have yet to be approved by the U.S. Food and Drug Administration, she might find something new that will give her more time with her husband and son.
4/22/18 - New hope in fight against ovarian cancer; Early trial shows targeted therapy looks promising
Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope. One study found that a new targeted "immunotherapy" to treat ovarian cancer that has come back looked promising in a small, early trial. Eva Chalas, director of the Center for Cancer Care at NYU Winthrop Hospital in Mi
4/22/18 - Novel Antioxidant Makes Old Blood Vessels Seem Young Again [FARS News Agency]
The study, published this week in the American Heart Association journal Hypertension, adds to a growing body of evidence suggesting pharmaceutical-grade nutritional supplements, or nutraceuticals, could play an important role in preventing heart disease-the nation's No. 1 killer. "This is the first clinical trial to assess the impact of a...
4/22/18 - Patent Issued for Uses of Cistanche Tubulosa Extract and Isoacteoside in Protecting Muscle (USPTO 9931367)
By a News Reporter-Staff News Editor at Heart Disease Weekly According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Wang, Chao-Jih; Yeh, Ai-Ling, filed on January 11, 2017, was published online on April 3, 2018. The assignee for this patent, patent number 9931367, is Sinphar Tian-Li Pha
4/22/18 - Scott Meacham: Great Oklahoma stories of entrepreneurship
If you are a regular reader of these columns, and I hope you are, you can tell that I like history. Take Novazyme Pharmaceuticals, founded by William Canfield, M.D., Ph.D., formerly a scientist at the University of Oklahoma Health Sciences Center and taken through a much-heralded exit by CEO John Crowley. Crowley, an experienced drug industry execu
4/22/18 - Ultrasound Device For Imaging Jonny 4757/aku/18 [TendersInfo (India)]
National contract notice: Ultrasound device for imaging Jonny 4757/ Aku/18. Tuomi Logistics Oy asks the Pirkanmaa Hospital District Imaging Center-and is behalf of the State Enterprise pharmacy Radiology Responsibility Promotions Ultrasound Imaging Device Tays Hatanp. Major organization: PIRKANMAAN SAIRAANHOITOPIIRIN KUNTAYHTYM Address:...
4/21/18 - "Beam Shaping Assembly for Neutron Capture Therapy" in Patent Application Approval Process (USPTO 20180085604)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors Liu, Yuan-Hao; Lee, Pei-Yi, filed on November 29, 2017, was made available online on April 5, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. By virtue of specific grouping of boronated pharm
4/21/18 - 10xBio Raises $2.7M to Test Body Sculpting Drug in Clinical Trial [Syrian Arab News Agency]
John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup hes leading has raised $2.66 million to advance a drug that is already approved to shrink varicose veins through early-stage clinical trials testing it in a new use fat reduction body sculpting. The biotech, 10 xBio, announced earlier this month that the FDA had approv
4/21/18 - 14501 - Polyaxial Pedicular Screw with Single Locking System, 6-7 Mm Diameter, Any Length, Titanium with Inne-Imported, Us Fda Approved, Make of Meditronics or Synthes or Zimmer only. 16038 - Polyaxial Pedicular Screw with Head and Locking, 4.0 Mm -
Ministry/Department Ministry of Railways Dr. Babasaheb Ambedekar Memorial Hospital, Central Railway Dr Ambedekar Road, Byculla East MUMBAI Attn: Md/Byculla-Medical/Central Rly. Description: Tenders are invited for 14501- Polyaxial Pedicular Screw with Single Locking System, 6-7 Mm Diameter, Any Length, Titanium with Inne-Imported, Us Fda Approved,
4/21/18 - Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease [All Iraq News Agency (AIN)]
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeonas gene therapy program ABO-202 for...
4/21/18 - An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR.)
GW Pharmaceuticals plc's cannabis-based drug for epilepsy, Epidiolex, won the unanimous backing of an advisory panel to the FDA on April 19, 2018. The FDA's final decision on Epidiolex is expected by June 27, 2018. If approved, Epidiolex would be the first-ever medicine derived from a marijuana plant to be greenlighted by the FDA.
4/21/18 - Anger against PM Modi's remarks in UK on Indian doctors not prescribing generic drugs [New Indian Express (India)]
NEW DELHI: Doctors from several parts of the country have said that PM Modi's "unjust" and "uncalled for" remarks in the UK on most doctors in India not prescribing generic drugs and getting sponsorships from pharmaceutical companies for foreign trips have "humiliated" them. "Your comments on us in the UK is a big setback for medical tourism in In
4/21/18 - AZs Tagrisso approved for untreated lung cancer in US [Tehran Times (Iran)]
AstraZenecas Tagrisso looks set to gain further traction after the FDA approved it in first-line treatment for lung cancer patients with a certain mutation. Dr Suresh Ramalingam, principal investigator of the FLAURA trial, from Winship Cancer Institute of Emory University, Atlanta, said: The approval of osimertinib in the first-line setting represe
4/21/18 - Bellicum Pharmaceuticals Announces Closing of Public Offering [T-break Tech (Middle East)]
-Bellicum Pharmaceuticals, Inc. a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold...
4/21/18 - Bluebird Bio One Step Closer to First Approved Drug [Arab News (Saudi Arabia)]
Bluebird bio, headquartered in Cambridge, Massachusetts, announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia. The two studies are Northstar, which was recently completed, and HGB-205, which is still proceeding. These interim data demonstrate the potential of...
4/21/18 - Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, in partnership with Takeda Pharmaceutical Company Ltd., Deerfield Management and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non-profit Tri-Institutional Therapeutics Discovery..
4/21/18 - Celltrion`s Truxima approved in Australia [Arab Finance (Egypt)]
South Korean biopharmaceutical firm Celltrion Inc. said Friday it has won an approval from an Australian regulator for the sale of its biosimilar drug Truxima. The Therapeutic Goods Administration accepted Celltrion`s application to sell the biosimilar to Roche`s Mabthera, the company said. The antibody biosimilar is used in the treatment of a numb
4/21/18 - Dr. Bob Harman, CEO of VetStem Biopharma, Speaks on Stem Cells at Second Annual International Regenerative Medicine Conference in Costa Rica [Sport360]
Bob Harman, founder and CEO of VetStem Biopharma, Inc., has been asked to speak at the second annual International Regenerative Medicine Conference which will take place on April 25-26, 2018 in Costa Rica. Dr. Harman has been a leader in the field of regenerative medicine for over a decade and has presented on the topic at both human and animal con
4/21/18 - Drugmakers compete to develop liver drugs [All Iraq News Agency (AIN)]
To widen live treatment options, Pharmicell, HLB Life Science, SillaJen, Samil Pharmaceutical, and Hanmi Pharmaceutical are accelerating researches on various drug candidates. Pharmicell, which has a stem cell treatment called Hearticellgram, is waiting to obtain conditional approval for Cellgram LC, a stem cell therapy for cirrhosis.
4/21/18 - Expanding Conditional Approvals in Animal Drug User Fee Act Is Bad for Public Health
U.S. PIRG delivered a letter signed by health professionals from across the country urging members of the House Energy and Commerce Committee not to expand conditional approvals when they consider the bill next week. Despite that threat, approximately 70% of the medically-important antibiotics sold in the U.S. each year go to food animals, and the
4/21/18 - Expanding Conditional Approvals in the Animal Drug User Fee Act Is Bad For Public Health
U.S. PIRG delivered a letter signed by health professionals from across the country urging members of the House Energy and Commerce Committee not to expand conditional approvals when they consider the bill next week. Despite that threat, approximately 70% of the medically-important antibiotics sold in the U.S. each year go to food animals, and the
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement